Hematopoietic stem cell transplantation and the principles of evidence-based medicine
Abstract
Similar changes in transplant activity were demonstrated in 1990–2000 years with allogeneic hematopoietic stem cells transplantations (HSCT) for chronic myeloid leukemia and autologous HSCT for breast cancer. The rise and fall of transplant activity for two specific indications within a short period are of interest as example of effective or not effective solutions. Ignoring the principles of evidence-based medicine is unacceptable in the era of high-tech and very expensive medicine with medical, economic and social reasons.
Downloads
References
Atkins D., Siegel J., Slutsky J. Making Policy When The Evidence Is In Dispute. Good health policy making involves consideration of much more than clinical evidence // Health Affairs. – 2005. – Vol. 24, N 1. – P. 102–113.
Baccarani M., Cortes J., Pane F. et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet // J. Clin. Oncol. – 2009. – Vol. 27, N 35. – P. 6041–6051.
Baccarani M., Saglio G., Goldman J. M. еt al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet // Blood. – 2006. – Vol. 108, N 6. – Р. 1809–1820.
Gratwohl A. The EBMT risk score // Bone Marrow Transplantation. – 2012. – Vol. 47. – P. 749–756.
Gratwohl A., Baldomero H., Aljurf M. et al. Hematopoietic stem cell transplantation: A Global Perspective // JAMA. – 2010. – Vol. 303, N 16. – P. 1617–1624.
Gratwohl A., Baldomero H., Demirer T. et al. Hematopoetic stem cell transplantation for solid tumors in Europe // Annals of Oncology. – 2004. – Vol. 15. – P. 653–660.
Gratwohl A., Baldomero H., Passweg J. et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe // Leukemia. – 2003. – Vol. 17. – P. 941–959.
Gratwohl A., Baldomero H., Schwendener A. et al. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe – impact of cost considerations // Leukemia. – 2007. – Vol. 21, N 3. – Р. 383–386.
Gratwohl A., Brand R., Apperley J. et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) // Haematologica. – 2006. – Vol. 91, N 4. – Р. 513–521.
Gratwohl A., Hermans J., Goldman J. M., Arcese W. Risk assessment for рatients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation // Lancet. – 1998. – Vol. 352, N 9134. – P. 1087–1092.
Jain N., van Besien K. Chronic myelogenous leukemia: Role of stem cell transplant in the Imatinib era // Hematol. Oncol. Clin. North Am. – 2011. – Vol. 25, N 5. – Р. 1025–1048.
Mello M. M., Brennan T. A. The Controversy Over High-Dose Chemotherapy With Autologous Bone Marrow Transplant For Breast Cancer // Health Affairs. – 2001. – Vol. 20, N 5. – P. 101–117.
Passweg J. R., Baldomero H., Gratwohl A. et al. The EBMT activity survey: 1990–2010 // Bone Marrow Transplantation. – 2012. – P. 1–18.
Passweg J. R., Walker I., Sobocinski K. A. et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants // British J. of Haematology. – 2004. – Vol. 125. – P. 613–620.
Radich J. Stem cell transplant for CML in the imatinib era // Semin. Hematol. – 2010. – Vol. 47, N 4. – Р. 354–361.
Abstract views: 110 PDF Downloads: 46
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
